Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782

Article  CAS  PubMed  Google Scholar 

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY et al (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168(5):317–325

Article  PubMed  PubMed Central  Google Scholar 

Hekimoğlu H, Toprak SF, Sözer S (2022) JAK2V617F-positive endothelial cells induce apoptosis and release JAK2V617F-positive microparticles. Turk J Hematol 39(1):13–21

Article  Google Scholar 

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hultcrantz M, Kristinsson SY, Andersson TML, Eloranta S, Derolf ÅR, Landgren O et al (2010) Patterns of survival and causes of death In 9,384 patients with myeloproliferative neoplasms diagnosed in Sweden between 1973 and 2008. Blood 116(21):3071

Article  Google Scholar 

Leiva O, How C-J, Brunner AM, Hobbs GS (2022) Trends in all-cause and cardiovascular mortality among patients with myeloproliferative neoplasms: a surveillance, epidemiology, and end results database analysis. Blood 140(Supplement 1):6808–6809

Article  Google Scholar 

Andıç N, Ünübol M, Yağcı E, Akay OM, Yavaşoğlu İ, Kadıköylü VG et al (2016) Clinical features of 294 Turkish patients with chronic myeloproliferative neoplasms. Turk J Hematol 33(3):187–195

Article  Google Scholar 

Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P et al (2015) Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 94(6):911–918

Article  PubMed  Google Scholar 

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML et al (2016) High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 30(10):2032–2038

Article  PubMed  Google Scholar 

Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G et al (2017) Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol 106(4):517–521

Article  CAS  PubMed  Google Scholar 

Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C et al (2019) High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 98(1):93–100

Article  PubMed  Google Scholar 

Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM et al (2018) Rivaroxaban and Apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc 93(1):40–47

Article  CAS  PubMed  Google Scholar 

Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581

Article  PubMed  Google Scholar 

Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makam RCP, Hoaglin DC, McManus DD, Wang V, Gore JM, Spencer FA et al (2018) Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis. PLoS ONE 13(5):e0197583

Article  PubMed  PubMed Central  Google Scholar 

Navar AM, Kolkailah AA, Overton R, Shah NP, Rousseau JF, Flaker GC et al (2022) Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc 11(22):e026723

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing G-J et al (2021) Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):2247–2259

Article  PubMed  Google Scholar 

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41(16):3063–3071

Article  CAS  PubMed  Google Scholar 

Schoenbeck KL, Salmasi G, Cerejo MC, Cornett PA, Damon LE, Logan AC et al (2019) Direct oral anticoagulant use and outcomes in patients with high and intermediate risk BCR-ABL-negative myeloproliferative neoplasms. Blood 134(1):1165

Article  Google Scholar 

Curto-Garcia N, Doyle AJ, Breen KA, McLornan DP, Radia DH, Hunt BJ et al (2020) Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. Br J Haematol 189(3):e79–e81

Article  PubMed  Google Scholar 

How J, Story C, Ren S, Neuberg D, Rosovsky RP, Hobbs GS et al (2021) Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J 11(11):176

Article  PubMed  PubMed Central  Google Scholar 

Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694

Article  CAS  PubMed  Google Scholar 

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126

Article  CAS  PubMed  Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 36(7):1703–19

Falanga A, Marchetti M, Schieppati F (2021) Prevention and management of thrombosis in BCR/ABL-negative myeloproliferative neoplasms. Hamostaseologie 41(1):48–57

Article  PubMed  Google Scholar 

Jones E, Dillon B, Swan D, Thachil J (2022) Practical management of the haemorrhagic complications of myeloproliferative neoplasms. Br J Haematol 199(3):313–321

Article  PubMed  PubMed Central  Google Scholar 

Wille K, Huenerbein K, Jagenberg E, Sadjadian P, Becker T, Kolatzki V et al (2022) Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): a retrospective single-center study of 829 MPN patients. Eur J Haematol 108(2):154–162

Article  CAS  PubMed  Google Scholar 

Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711–719

Article  CAS  PubMed  Google Scholar 

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720–728

Article  CAS  PubMed  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421

Article  CAS  PubMed